ioflupane I 123 (Rx)

Brand and Other Names:DaTscan
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

intravenous injection: Schedule II

  • 185 MBq/2.5mL

Dopamine Transporter Visualization

Radiopharmaceutical indicated for

  • Striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adults with suspected Parkinsonian syndromes (PS) or suspected dementia with Lewy bodies (DLB)
  • Help differentiating essential tremor from tremor due to PS (idiopathic Parkinson disease, multiple system atrophy and progressive supranuclear palsy)

Dose

  • Measure dose by a suitable radioactivity calibration system immediately before administering
  • Administer thyroid-blocking agent (eg, potassium iodide oral solution, potassium perchlorate) at least 1 hr before dose
  • Recommended dose is 111-185 MBq (3-5 mCi)
  • Begin SPECT imaging 3-6 hr post-injection
  • Thyroid blockade
    • Administer 1 hr before DaTscan dose
    • Potassium iodide oral solution (or Lugol’s Solution) equivalent to 100 mg iodide, OR
    • Potassium perchlorate 400 mg

Renal Impairment

Excreted by kidneys

Severe renal impairment may increase radiation exposure to patient and alter images

Safety and efficacy not established

In the 2 principal clinical studies, 45% of the subjects were aged 65 yr or older

There were no differences in response compared to younger subjects that would require a dose adjustment

Other reported clinical experience has not identified differences in responses between the elderly and younger patients

Next:

Interactions

Interaction Checker

and ioflupane I 123

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (18)

                • amoxapine

                  amoxapine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I123 administration.

                • benztropine

                  benztropine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • bupropion

                  bupropion decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • buspirone

                  buspirone decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • citalopram

                  citalopram decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • cocaine topical

                  cocaine topical decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • dextroamphetamine

                  dextroamphetamine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • escitalopram

                  escitalopram decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • iodixanol

                  iodixanol decreases effects of ioflupane I 123 by unknown mechanism. Use Caution/Monitor. Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with thyroid carcinoma. Decreased efficacy lasts for 6-8 weeks. .

                • metformin

                  ioflupane I 123 increases toxicity of metformin by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Administration of intravascular iodinated contrast agents in metformin-treated patients has led to rare cases of acute decrease in renal function and the occurrence of lactic acidosis. The American College of Radiology Guidelines (2018) recommend temporarily stopping metformin in patients with eGFR is <30 mL/min/1.73 m2 or who are undergoing arterial catheter studies that might result in emboli to the renal arteries. Continue to withhold metformin for 48 hr subsequent to the procedure and reinstituted only after renal function has been reevaluated and found to be normal. .

                • methamphetamine

                  methamphetamine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • norepinephrine

                  norepinephrine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • paroxetine

                  paroxetine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • phentermine

                  phentermine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • selegiline

                  selegiline decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • selegiline transdermal

                  selegiline transdermal decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • sertraline

                  sertraline decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.

                • voclosporin

                  voclosporin, ioflupane I 123. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

                Minor (0)

                  Previous
                  Next:

                  Adverse Effects

                  <1%

                  Headache

                  Nausea

                  Dizziness

                  Vertigo

                  Xerostomia

                  Postmarketing Reports

                  Immune system disorders: Hypersensitivity, including dyspnea, edema, rash, erythema, and pruritus

                  General disorders and administration site conditions: Injection site pain

                  Previous
                  Next:

                  Warnings

                  Contraindications

                  Hypersensitivity to active substance, excipients, or iodine

                  Cautions

                  May cause hypersensitivity reactions depicted by skin erythema and pruritus; these reactions have generally occurred within minutes of administration and have either resolved spontaneously or following administration of corticosteroids and antihistamines; contraindicated with known hypersensitivity to ioflupane I 123; have treatment measures available and monitor patients for symptoms or signs of a hypersensitivity reaction

                  Thyroid accumulation of iodine-123 may occur; to decrease thyroid accumulation of Iodine-123, block the thyroid gland (eg, potassium iodide) before administration of therapy; failure to block thyroid uptake of I-123 may result in an increased long-term risk for thyroid neoplasia

                  Radiation risk

                  • Contributes to patient’s overall long-term cumulative radiation exposure and its associated increased risk for cancer
                  • Ensure safe handling to minimize radiation exposure to patients and clinicians
                  • Bladder protection
                    • Minimize radiation dose to bladder by encouraging hydration before and following administration
                    • Encourage patient to void frequently for first 48 hr following administration

                  Drug interaction overview

                  • Drugs that bind to dopamine transporter with high affinity may interfere with image
                  • Effects of dopamine agonists and antagonists on ioflupane I 123 imaging have not been established
                  • Drugs that may interfere with ioflupane binding include
                    • Amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline
                  • Drugs that may increase or decrease ioflupane binding include
                    • Citalopram and paroxetine
                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy

                  Radioactive iodine products cross the placenta and can permanently impair fetal thyroid function; administration of an appropriate thyroid blocking agent is recommended before use in a pregnant woman to protect the woman and fetus from accumulation of iodine

                  There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; advise pregnant women of potential risks of fetal exposure to radiation doses with administration of product

                  Animal data

                  • Animal reproduction studies have not been conducted with ioflupane I 123; all radiopharmaceuticals have the potential to cause fetal harm depending on fetal stage of development and magnitude of radiation dose; administration at a dose of 185 MBq (5 mCi) results in an absorbed radiation dose to uterus of 0.3 rad (3.0 mGy)
                  • Radiation doses >15 rad (150 mGy) have been associated with congenital anomalies but doses under 5 rad (50 mGy) generally have not

                  Lactation

                  Iodide 123 (I 123), the radionuclide, is present in human milk; there is no information on effects on breastfed infant or on milk production; advise a lactating woman to interrupt breastfeeding and pump and discard breastmilk for at least 6 days (>10 physical half-lives) after administration in order to minimize radiation exposure to a breastfed infant

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  Binds reversibly to the human recombinant dopamine transporter (DaT) (Ki = 0.62 nM; IC50 = 0.71 nM)

                  Following administration, radioactive decay of the iodine123 emits gamma radiation which can be detected externally using gamma detectors, allowing visualization of the brain striata through SPECT imaging

                  Pharmacokinetics

                  Half-Life: 13.2 hr

                  Brain uptake: 7% of injected radioactivity at 10 min post-injection; decreased to 3% at 5 hr post-injection

                  Onset: ~7% of radioactivity in brain within 10 min

                  Metabolism: Decays to 123Te by electron capture

                  Excretion: feces (14% by 48 hr), urine (60% by 48 hr)

                  Previous
                  Next:

                  Administration

                  IV Preparation

                  IV injection: Use aseptic procedures and radiation shielding during preparation and administration

                  Inspect vial before administering and discard if vial contains particulate matter or discoloration

                  IV Administration

                  Slow IV injection (administer over at least 15-20 seconds) via an arm vein

                  Have medications and medical support to respond to anaphylaxis readily available

                  Storage

                  Store within original lead container or equivalent radiation shielding

                  Do not use after expiration date and time stated on label

                  Emits radiation and must be handled with safety measures to minimize radiation exposure to clinical personnel and patients

                  Previous
                  Next:

                  Images

                  No images available for this drug.
                  Previous
                  Next:

                  Patient Handout

                  Patient Education
                  ioflupane I 123 intravenous

                  NO MONOGRAPH AVAILABLE AT THIS TIME

                  USES: Consult your pharmacist.

                  HOW TO USE: Consult your pharmacist.

                  SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

                  PRECAUTIONS: Consult your pharmacist.

                  DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

                  OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

                  NOTES: No monograph available at this time.

                  MISSED DOSE: Consult your pharmacist.

                  STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

                  Information last revised July 2016. Copyright(c) 2022 First Databank, Inc.

                  IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  Additional Offers
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.